α-Glucosidase-IN-23

α-Glucosidase-IN-23 is an orally active α-Glucosidase inhibitor. α-Glucosidase-IN-23 decreases blood glucose by a-glucosidase inhibition with an IC50 value of 4.48 μM. α-Glucosidase-IN-23 can be used for the research of diabetes[1].

Research Areas >> Metabolic Disease

IC50: 4.48 μM (a-glucosidase)[1].

α-Glucosidase-IN-23 (compound 8b) (1 μM) 具有显著的抗糖尿病作用[1]。 α-Glucosidase-IN-23 减少 β 细胞和肌肉细胞中的 ROS[1]。 α-Glucosidase-IN-23 通过抑制 a-glucosidase 降低血糖，IC50 值为 4.48 μM[1]。 Cell Proliferation Assay[1] Cell Line: INS-1 Cells Concentration: 1 μM Incubation Time: Result: Stimulated the growth of INS-1 cells in a dose-codependent approach. Apoptosis Analysis[1] Cell Line: INS-1 Cells Concentration: 1 μM Incubation Time: Result: Restored the viability of INS-1 cells by about five times from apoptosis and eight times from necrosis.

α-Glucosidase-IN-23（口服；0.2 mmol/kg/天）仅抑制小鼠体内的 α-葡萄糖苷酶[1]。 Animal Model: Mice[1] Dosage: 0.2 mmol/kg Administration: Oral; 0.2 mmol/kg/day Result: Cmax (nmol/mL) Tmax (h) T1/2(h) AUC (ng/h/mL) 10.11 ± 1.17 0.8 ± 0.0 1.90 ± 1.04 36.7 ± 2.23

[1]. Peter A Sidhom, et al. Mechanistic Insight of Synthesized 1,4-Dihydropyridines as an Antidiabetic Sword against Reactive Oxygen Species. J Med Chem. 2023 Jan 12;66(1):991-1010.